Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Last week's survey by the British Potato Council revealed that we prefer mash to chips. So is this good news for our health? Nutritionally speaking, both mash and chips are good sources of energy ...

Dr. Suresh Babu holds a PhD in materials science and metallurgy from University of Cambridge and is currently director of the Bredesen Center for Interdisciplinary Research and Graduate Education, as ...